Business Description
Chromocell Therapeutics Corp
NAICS : 541713
SIC : 8731
ISIN : US1711261057
Description
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.97 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 1.12 | |||||
Debt-to-EBITDA | -0.16 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -155.9 | |||||
3-Year EPS without NRI Growth Rate | -106.2 | |||||
3-Year FCF Growth Rate | 24.2 | |||||
3-Year Book Growth Rate | -42.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 6.97 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.28 | |||||
9-Day RSI | 38.52 | |||||
14-Day RSI | 40.5 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.39 | |||||
Quick Ratio | 1.39 | |||||
Cash Ratio | 1.3 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 14.7 | |||||
Shareholder Yield % | -91.24 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 6.28 | |||||
Price-to-Tangible-Book | 6.15 | |||||
EV-to-EBIT | -1.05 | |||||
EV-to-EBITDA | -1.05 | |||||
EV-to-FCF | -2.95 | |||||
Price-to-Net-Current-Asset-Value | 6.15 | |||||
Price-to-Net-Cash | 8.2 | |||||
Earnings Yield (Greenblatt) % | -95.24 | |||||
FCF Yield % | -39.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:CHRO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chromocell Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -1.662 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 40.5 | ||
14-Day ATR ($) | 0.14004 | ||
20-Day SMA ($) | 1.350585 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 1.21 - 6 | ||
Shares Outstanding (Mil) | 5.77 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Chromocell Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Chromocell Therapeutics Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Chromocell Therapeutics Corp Frequently Asked Questions
What is Chromocell Therapeutics Corp(CHRO)'s stock price today?
The current price of CHRO is $1.23. The 52 week high of CHRO is $6.00 and 52 week low is $1.21.
When is next earnings date of Chromocell Therapeutics Corp(CHRO)?
The next earnings date of Chromocell Therapeutics Corp(CHRO) is .
Does Chromocell Therapeutics Corp(CHRO) pay dividends? If so, how much?
Chromocell Therapeutics Corp(CHRO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |